Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM; Others investigators (SERC trial group). Houvenaeghel G, et al. Among authors: gabelle p. BMC Cancer. 2018 Nov 21;18(1):1153. doi: 10.1186/s12885-018-5053-7. BMC Cancer. 2018. PMID: 30463611 Free PMC article. Clinical Trial.
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM; SERC trial group. Houvenaeghel G, et al. Among authors: gabelle p. NPJ Breast Cancer. 2021 Oct 8;7(1):133. doi: 10.1038/s41523-021-00336-3. NPJ Breast Cancer. 2021. PMID: 34625562 Free PMC article.
Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.
Huguet M, Perrier L, Bally O, Benayoun D, De Saint Hilaire P, Beal Ardisson D, Morelle M, Havet N, Joutard X, Meeus P, Gabelle P, Provençal J, Chauleur C, Glehen O, Charreton A, Farsi F, Ray-Coquard I. Huguet M, et al. Among authors: gabelle p. BMC Health Serv Res. 2018 Jan 4;18(1):3. doi: 10.1186/s12913-017-2802-2. BMC Health Serv Res. 2018. PMID: 29301572 Free PMC article.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A. Coudert B, et al. Among authors: gabelle p. Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30. Lancet Oncol. 2014. PMID: 25456368 Clinical Trial.
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Coudert B, et al. Among authors: gabelle p. EClinicalMedicine. 2020 Nov 4;28:100566. doi: 10.1016/j.eclinm.2020.100566. eCollection 2020 Nov. EClinicalMedicine. 2020. PMID: 33205032 Free PMC article.
[Cytologic grade, a prognostic factor in breast cancer].
Mouriquand J, Bolla M, Gabelle P, Geindre M, Sage JC, Mouriquand C. Mouriquand J, et al. Among authors: gabelle p. J Gynecol Obstet Biol Reprod (Paris). 1982;11(4):471-6. J Gynecol Obstet Biol Reprod (Paris). 1982. PMID: 7142667 French.
[Pancreatic injuries. Report on 42 cases (author's transl)].
Laborde Y, Champetier J, Letoublon C, Aubert M, Gabelle P, Dyon JF, Vigneau B. Laborde Y, et al. Among authors: gabelle p. J Chir (Paris). 1982 Jan;119(1):47-54. J Chir (Paris). 1982. PMID: 7061612 French.
13 results